ABOUT
__24K27CHhPF.png)
ABOUT US
AcadeMab is focused on developing new antibody drugs for the unmet medical need. We also develop mRNA technology as a dual-engine platform, integrating it with antibody development to drive the advancement of vaccines and related biomedical products.
ADVANTAGE
AcadeMab focuses on groundbreaking science and patient-centric innovation to provide transformative therapies that make a lasting impact on global healthcare.
PIPELINE
__24K27q19R5.png)
-
Development progress
-
Discovery
-
Pre-clinical
-
Phase I
-
Phase II
__24K27xDIr9.png)
-
Development progress
-
Discovery
-
Pre-clinical
-
Phase I
-
Phase II
__24K27c2zcI.png)
AM-168 Anti-HER3 mAb
Indications:
Resistance to Anti-EGFR or Anti-HER2 therapies in breast cancer and lung cancer
-
Development progress
-
Discovery
-
Pre-clinical
-
Phase I
-
Phase II
__24K27h7Sh6.png)
SB-001 Anti-COVID-19 mAb
Indications:
COVID-19 (Severe Special Infectious Pneumonia)
-
Development progress
-
Discovery
-
Pre-clinical
-
Phase I
-
Phase II
Our Bio
__25G17osPeH.png)
__24L11GJopD.png)
Anti-M13 Antibody
AcadeMab develops a mouse monoclonal anti-M13 antibody which can specific recognize M13 phage coat protein P8.
Human Antibody Mouse
AcadeMab’s antibody mouse is developed by the replacement of the original mouse antibody genes to human antibody genes. This mouse strain can generate human antibodies that have been optimized naturally through in vivo affinity maturation.
Human Single B Cell Antibody Technology
Human single B cell antibody technology is an efficient and cutting-edge approach to discovery human monoclonal antibody from vaccine recipients or convalescent patients.
__24K27jKUKD.png)
Phage Display
Phage display is a molecular biology technique, that can be used to discover antibody or binding epitope by inserting the DNA sequence of scFv or peptide into the appropriate position of phage coat protein structural gene to be further expressed and displayed on the phage surface for a high throughput screening of desired targets.
